Drug-Drug Interaction between Pravastatin and Gliclazide in Animal Models

Satyanarayana, S.; Chandrasekhar, M. S.; Palakshi Gouda, O.; Eswar Kumar, K.

doi:https://doi.org/10.3814/2008/620489

Scholarly Research Exchange

On this page

Abstract References Copyright Related Articles

Research Article | Open Access

Volume 2008 | Article ID 620489 | https://doi.org/10.3814/2008/620489

Drug-Drug Interaction between Pravastatin and Gliclazide in Animal Models

S. Satyanarayana,¹M. S. Chandrasekhar,²O. Palakshi Gouda,¹and K. Eswar Kumar¹

Received17 May 2008

Revised31 May 2008

Accepted15 Aug 2008

Published03 Sept 2008

Abstract

The present study is planned to evaluate the safety of gliclazide (antidiabetic) therapy in the presence of pravastatin (antihyperlipidemic) in rats and rabbits. Studies in normal and alloxan-induced diabetic rats were conducted with oral doses of gliclazide, pravastatin, and their combination. Similarly, studies in normal rabbits were conducted with oral doses of gliclazide, pravastatin, and their combination with adequate washout periods in between the treatments. Blood samples were collected from rats and rabbits at different time intervals and were analyzed for blood serum gliclazide levels. Gliclazide produced hypoglycaemic/antihyperglycaemic activity in normal and diabetic rats with peak activity after 2 hours and 8 hours and hypoglycaemic activity in normal rabbits with peak activity after 3 hours. Pravastatin alone produced minor reduction in blood glucose levels in normal rats/diabetic rats/normal rabbits. Pravastatin increased the hypoglycaemic effect of gliclazide in normal rats/diabetic rats/normal rabbits when administered together. The serum insulin levels were increased with pravastatin treatment in rabbits. The serum gliclazide levels and pharmacokinetic parameters of gliclazide were altered significantly in presence of pravastatin in rabbits. The interaction observed appears to be pharmacokinetic interaction at metabolic and excretion levels.

References

F. M. Gribble, S. J. Tucker, S. Seino, and F. M. Ashcroft, “Tissue specificity of sulfonylureas studies on cloned cardiac and $β$ - cell $K_{ATP}$ channels,” Diabetes, vol. 47, no. 9, pp. 1412–1418, 1998.
View at: Publisher Site | Google Scholar
A. D. Harrower, “Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM,” Diabetes Research and Clinical Practice, vol. 14, pp. S65–S67, 1991.
View at: Publisher Site | Google Scholar
O. Ziegler and P. Drouin, “Hemobiological properties of gliclazide,” Journal of Diabetes and Its Complications, vol. 8, no. 4, pp. 235–239, 1994.
View at: Publisher Site | Google Scholar
H. Y. Pan, A. R. DeVault, B. J. Swites et al., “Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia,” Clinical Pharmacology and Therapeutics, vol. 48, no. 2, pp. 201–207, 1990.
View at: Google Scholar
I. Hsu, S. A. Spinler, and N. E. Johnson, “Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia,” Annals of Pharmacotherapy, vol. 29, no. 7-8, pp. 743–759, 1995.
View at: Google Scholar
T. Hatanaka, “Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events,” Clinical Pharmacokinetics, vol. 39, no. 6, pp. 397–412, 2000.
View at: Publisher Site | Google Scholar
W. Jacobsen, G. Kirchner, K. Hallensleben et al., “Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver,” Drug Metabolism and Disposition, vol. 27, no. 2, pp. 173–179, 1999.
View at: Google Scholar
C. Transon, T. Leemann, and P. Dayer, “In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors,” European Journal of Clinical Pharmacology, vol. 50, no. 3, pp. 209–215, 1996.
View at: Publisher Site | Google Scholar
V. Riley, “Adaptation of orbital bleeding technic to rapid serial blood studies,” Proceedings of the Society for Experimental Biology and Medicine, vol. 104, pp. 751–754, 1960.
View at: Google Scholar
P. Trinder, “Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen,” Journal of Clinical Pathology, vol. 22, no. 2, pp. 158–161, 1969.
View at: Publisher Site | Google Scholar
R. E. Heikkila, “The prevention of alloxan-induced diabetes in mice by dimethyl sulfoxide,” European Journal of Pharmacology, vol. 44, no. 2, pp. 191–193, 1977.
View at: Publisher Site | Google Scholar
K. Eswar Kumar, A. Ramesh, R. S. Yadav, and S. Satyanarayana, “Determination of gliclazide in rabbit serum by RP-HPLC,” Acta Ciencia Indica. Chemistry, vol. 33, no. 3, pp. 273–278, 2007.
View at: Google Scholar
H. Miyazaki, T. Fujii, K. Yoshida, S. Arakawa, and H. Furukawa, “Disposition and metabolism of $[{}^{3}H]$ gliclazide in rats,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 8, no. 2, pp. 117–131, 1983.
View at: Google Scholar
A. Benakis and B. Glasson, “Metabolic study of 14 C-labelled gliclazide in normal rats and in rats with streptozotocin-induced diabetes,” in Gliclazide and Treatment of Diabetes, H. Keen, Ed., pp. 57–69, Academic Press and the Royal Society of Medicine, London, UK, 1980.
View at: Google Scholar
D. E. Rollins and C. D. Klaassen, “Biliary excretion of drugs in man,” Clinical Pharmacokinetics, vol. 4, no. 5, pp. 368–379, 1979.
View at: Google Scholar
D. B. Campbell, R. Lavielle, and C. Nathan, “The mode of action and clinical pharmacology of gliclazide: a review,” Diabetes Research and Clinical Practice, vol. 14, pp. S21–S36, 1991.
View at: Publisher Site | Google Scholar
B. L. Wajchenberg, A. T. M. G. Santomauro, and R. N. Porrelli, “Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM),” Diabetes Research and Clinical Practice, vol. 20, no. 2, pp. 147–154, 1993.
View at: Publisher Site | Google Scholar
S. M. Singhvi, H. Y. Pan, R. A. Morrison, and D. A. Willard, “Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects,” British Journal of Clinical Pharmacology, vol. 29, no. 2, pp. 239–243, 1990.
View at: Google Scholar
R. E. Ferner and S. Chaplin, “The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs,” Clinical Pharmacokinetics, vol. 12, no. 6, pp. 379–401, 1987.
View at: Google Scholar
T. Oida, K. Yoshida, A. Kagemoto, Y. Sekine, and T. Higashijima, “The metabolism of gliclazide in man,” Xenobiotica, vol. 15, no. 1, pp. 87–96, 1985.
View at: Google Scholar

Copyright

Copyright © 2008 S. Satyanarayana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

557

Downloads

0

Citations